RT Book, Section A1 Aquilante, Christina L. A1 Page, Robert L. A2 Bertino, Joseph S. A2 DeVane, C. Lindsay A2 Fuhr, Uwe A2 Kashuba, Angela D. A2 Ma, Joseph D. SR Print(0) ID 56876674 T1 Chapter 11. Cardiovascular Pharmacogenomics T2 Pharmacogenomics: An Introduction and Clinical Perspective YR 2013 FD 2013 PB The McGraw-Hill Companies PP New York, NY SN 978-0-07-174169-9 LK accesspharmacy.mhmedical.com/content.aspx?aid=56876674 RD 2024/03/28 AB Identify key candidate genes and polymorphisms that influence the pharmacokinetics, clinical response, and toxicity of cardiovascular medications.Describe, in depth, how key polymorphisms affect the pharmacokinetics, clinical response, and toxicity of cardiovascular medications such as clopidogrel, statins, and β-blockers.Discuss the role of genome-wide association studies in identifying genes and polymorphisms associated with response to cardiovascular medications.Weigh the evidence of available pharmacogenomic literature to determine the clinical utility of genetic testing in the management of cardiovascular diseases.Using a case-based approach, illustrate how genomic information may be used to guide drug selection and management of clopidogrel and statins.